Pyxis Oncology secured up to $114 million through a private placement led by BVF Partners to fund the development of its cancer drug MICVO. The financing will extend the company's cash runway into Q2 2027, supporting ongoing trials for head and neck squamous cell carcinoma. Updated Phase 1 monotherapy data is expected in Fall 2026, with combination therapy data due in Q4 2026. This funding strengthens Pyxis's ability to advance MICVO toward regulatory and clinical milestones, aiming to improve treatment for difficult cancers.
Cause + Effect Strategy (CES) and StackAI have formed a strategic partnership to help mid-market and enterprise organizations implement AI solutions that deliver real business outcomes. CES brings expertise in data strategy and analytics infrastructu...
Aikido Security has acquired Root to improve the security of open source software by enabling AI agents to research, patch, and test vulnerabilities without forcing teams to upgrade or migrate. This approach addresses the growing threat of supply cha...
Nutanix has donated $250,000 to the North Carolina School of Science and Mathematics (NCSSM) to establish an endowed professorship aimed at expanding computer science education across North Carolina. This funding supports teacher training and open-so...
Wetour Robotics has demonstrated its Conductor neural wristband that converts wrist muscle signals into a real-time 3D digital twin of the hand and translates hand gestures into text commands without cameras or gloves. This technology, built on Meta'...
DLP Real Estate Capital closed a $118 million refinancing deal for its Houston multifamily portfolio, which includes 605 units across two communities: Elan Memorial and City Park in the Heights. The new floating-rate loan has a 36-month term with ext...
